Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group (Journal article)

Bamias, A./ Aravantinos, G./ Kalofonos, C./ Timotheadou, N./ Siafaka, V./ Vlahou, I./ Janinis, D./ Pectasides, D./ Pavlidis, N./ Fountzilas, G.

OBJECTIVES: Platinum compounds are commonly associated with significant anemia. Erythropoietin administration has been found effective in correcting anemia in patients with solid tumors receiving chemotherapy. We conducted a randomized, open label study to assess the efficacy of erythropoietin in preventing transfusions and significant anemia (hemoglobin <10 g/dl) in patients with solid tumors receiving platinum-based chemotherapy. METHODS: One hundred forty-four patients with hemoglobin <13 g/dl were included in this study (72 in each arm). Patients in the treatment arm received 10,000 U of recombinant human erythropoietin (rHuEPO) thrice weekly s.c. during platinum-based chemotherapy, while patients in the control arm received no treatment. RESULTS: All patients were evaluable for efficacy. Transfusions were reduced by the administration of rHuEPO (15.3 vs. 33.3%, p = 0.019), and fewer patients developed significant anemia (16.6 vs. 45.8%, p < 0.0001). Subgroup analysis showed that patients with observed to predicted (O/P) serum erythropoietin levels 0.9 or non-responders. CONCLUSIONS: rHuEPO at a dose of 10,000 U thrice weekly prevents transfusions and development of significant anemia in patients with solid tumors receiving platinum-based chemotherapy.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,Aged, 80 and over,Anemia, Hypochromic/chemically induced/*prevention & control,Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse,effects,Blood Transfusion,Erythropoietin/administration & dosage/*therapeutic use,Female,Greece,Humans,Male,Middle Aged,Neoplasms/*drug therapy,Organoplatinum Compounds/administration & dosage/*adverse effects,Prognosis,Prospective Studies,Quality of Life,Recombinant Proteins,Risk Factors,Treatment Outcome
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/19082
ISSN: 0030-2414
Link: http://www.ncbi.nlm.nih.gov/pubmed/12566906
http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000067766&Ausgabe=228855&ProduktNr=223857&filename=000067766.pdf
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Bamias-2003-Prevention of anemia.pdf110.43 kBAdobe PDFView/Open    Request a copy


 Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19082
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.